BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zarrabi K, Walzer E, Zibelman M. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. Cancers (Basel) 2021;13:3652. [PMID: 34359554 DOI: 10.3390/cancers13153652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 John A, Spain L, Hamid AA. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. Curr Oncol 2023;30:923-37. [PMID: 36661719 DOI: 10.3390/curroncol30010070] [Reference Citation Analysis]
2 Khoshdel Rad N, Vahidyeganeh M, Mohammadi M, Shpichka A, Timashev P, Hossein-khannazer N, Vosough M. Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches. IJTM 2022;2:555-573. [DOI: 10.3390/ijtm2040042] [Reference Citation Analysis]
3 Vento JA, Rini BI. Treatment of Refractory Metastatic Renal Cell Carcinoma. Cancers 2022;14:5005. [DOI: 10.3390/cancers14205005] [Reference Citation Analysis]
4 Zhang L, Hobeika CS, Khabibullin D, Yu D, Filippakis H, Alchoueiry M, Tang Y, Lam HC, Tsvetkov P, Georgiou G, Lamb C, Stone E, Puigserver P, Priolo C, Henske EP. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. Proc Natl Acad Sci U S A 2022;119:e2122840119. [PMID: 35867762 DOI: 10.1073/pnas.2122840119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Adashek JJ, Breunig JJ, Posadas E, Bhowmick NA, Ellis L, Freedland SJ, Kim H, Figlin R, Gong J. First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been? Drugs 2022. [PMID: 35175588 DOI: 10.1007/s40265-022-01683-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Martini DJ, Jansen CS, Harik LR, Evans ST, Olsen TA, Master VA, Kissick HT, Bilen MA. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Front Oncol 2021;11. [DOI: 10.3389/fonc.2021.793808] [Cited by in F6Publishing: 1] [Reference Citation Analysis]